Preprint Article Version 1 This version is not peer-reviewed

Selective Cytotoxic Activity and DNA Damage by an Epoxyalkyl Galactopyranoside

Version 1 : Received: 26 April 2018 / Approved: 27 April 2018 / Online: 27 April 2018 (14:00:47 CEST)

How to cite: Burgos-Morón, E..; Pastor, N..; Orta, M.L..; Jiménez-Alonso, J.J.; Vega-Holm, M..; Vega-Pérez, J.M..; Iglesias-Guerra, F..; Mateos, S..; Lopez-Lazaro, M.; Calderón-Montaño, J.M.. Selective Cytotoxic Activity and DNA Damage by an Epoxyalkyl Galactopyranoside. Preprints 2018, 2018040360 (doi: 10.20944/preprints201804.0360.v1). Burgos-Morón, E..; Pastor, N..; Orta, M.L..; Jiménez-Alonso, J.J.; Vega-Holm, M..; Vega-Pérez, J.M..; Iglesias-Guerra, F..; Mateos, S..; Lopez-Lazaro, M.; Calderón-Montaño, J.M.. Selective Cytotoxic Activity and DNA Damage by an Epoxyalkyl Galactopyranoside. Preprints 2018, 2018040360 (doi: 10.20944/preprints201804.0360.v1).

Abstract

Several clinically useful anticancer drugs selectively kill cancer cells by inducing DNA damage; the genomic instability and DNA repair defects of cancer cells make them more vulnerable than normal cells to the cytotoxicity of DNA-damaging agents. Because epoxide-containing compounds can induce DNA damage, we have used the MTT assay to evaluate the selective cytotoxicity of three epoxyalkyl galactopyranosides against A549 lung cancer cells and MRC-5 lung normal cells. Compound (2S,3S)-2,3-Epoxydecyl 4,6-O-(S)-benzylidene-β-D-galactopyranoside (EDBGP) showed the highest selective anticancer activity and was selected for mechanistic studies. After observing that EDBGP induced cellular DNA damage (comet assay), we found that cells deficient in nucleotide excision repair were hypersensitive to the cytotoxicity of this compound; this suggests that EDBGP may induce bulky DNA adducts. EDBGP did not inhibit glycolysis (glucose consumption and lactate production). Pre-treatment of lung cancer cells with several antioxidants did not reduce the cytotoxicity of EDBGP, thereby indicating that reactive oxygen species do not participate in the anticancer activity of this compound. Finally, EDBGP was screened against a panel of cancer cells and normal cells from several tissues, including three genetically modified skin fibroblasts with increasing degree of malignancy. Our results suggest that epoxyalkyl galactopyranosides are promising lead compounds for the development of new anticancer agents.

Subject Areas

epoxide, cancer, anticancer, cytotoxicity, nucleotide excision repair

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.